Pharmaceuticals

How Is The Humira Drug Market Expected To Grow At 7.8% CAGR Over 2025–2029?

October 15, 2025 by Marketing Posting

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

#How Is The Humira Drug Market Expected To Grow In Terms Of Size?#_x000D_

The market size of the Humira drug has been expanding robustly in the previous years. From $9.74 billion in 2024, it is expected to rise to $10.33 billion in 2025, resulting in a compound annual growth rate (CAGR) of 6.0%. This expansion throughout the historical duration is thanks to the introduction of biologics, advancements in biotechnology, the need of patients for efficient treatments, and the patterns of adoption and prescription by doctors._x000D_

_x000D_

The size of the Humira drug market is predicted to increase significantly in the upcoming years, expanding to “$13.93 billion by 2029” with a compound annual growth rate (CAGR) of 7.8%. This projected growth during the forecast period can be credited to factors such as the entry of biosimilars into the market, alterations in healthcare policies, emphasis on cost-efficient strategies, investment in research and development, precision treatments, and personalized therapies. The forecast also suggests major trends including the generation of real-world evidence, the broadening usage in children, the move towards self-administered medication, adoption of value-based pricing modules, and development of targeted therapies._x000D_

_x000D_

#Get A Free Sample Of The Report:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=11934&type=smp_x000D_

_x000D_

#Which Key Factors Are Fueling Growth In The Humira Drug Market?#_x000D_

The surge in the occurrence of autoimmune diseases is set to catalyze the expansion of the humira drug market in the future. Autoimmune disease is characterized by the body’s immune system targeting and eradicating healthy tissues and cells within the body. The Humira drug, utilized to alleviate pain and inflammation resulting from various autoimmune disorders, sees a corresponding climb in demand due to this surge in autoimmune diseases. The National Health Council, a non-profit organization based in the US, noted in March 2024 that about 50 million Americans are affected by autoimmune diseases. However, owing to the diagnostic difficulties associated with these conditions, this number is probably underestimated. Even more alarming is that autoimmunity is nearing epidemic levels, with certain reports suggesting an annual rise of 3-12%. Thus, the escalating occurrence rate of autoimmune diseases will fuel the HUMIRA drug market._x000D_

_x000D_

#Which Segmentation Categories Are Highlighted In The Humira Drug Market Analysis?#_x000D_

The humira drug market covered in this report is segmented – _x000D_

_x000D_

1) By Type: Humira Syringe, Humira Pen_x000D_

2) By Application: Ankylosing Spondylitis, Rheumatoid Arthritis, Crohn’s Disease, Other Applications_x000D_

3) By End-Users: Hospitals, Specialty Clinics, Other End-Users_x000D_

_x000D_

Subsegments:_x000D_

1) By Humira Syringe: Pre-Filled Syringe, Disposable Syringe _x000D_

2) By Humira Pen: Auto-Injector Pen, Pre-Filled Injection Pen _x000D_

_x000D_

#Which Market Trends Are Expected To Define The Future Of The Humira Drug Market?#_x000D_

Innovations in products stand out as a prevalent trend in the humira drug market. The leading businesses in this market are pioneering new biologics and biosimilars to maintain their market presence. For example, Sandoz, a pharmaceutical company based in Switzerland, launched Biosimilar Hyrimoz (adalimumab), a citrate-free high-concentration formulation (HCF) in April 2023, which was sanctioned by the European Commission. The 100 mg/mL formulation of adalimumab citrate-free HCF slashes the injection volume by 50% and lessens the count of injections needed for patients choosing 80 mg/mL or higher dosage. This aids patients with a variety of conditions such as rheumatic diseases, Crohn’s disease, and more, thereby enriching their patient experience._x000D_

_x000D_

#Which Players Are Shaping The Competitive Landscape Of The Humira Drug Market?#_x000D_

Major companies operating in the humira drug market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Fresenius Kabi AG, Amgen Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sandoz International GmbH, Hikma Pharmaceuticals PLC, Celltrion Healthcare Co. Ltd., Cadila Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Mochida Pharmaceutical Co. Ltd., Innovent Biologics Inc., Biocad Biopharmaceutical Company, Shanghai Henlius Biotech Inc., Glenmark Pharmaceuticals Ltd., Samsung Bioepis Co Ltd., Hetero Healthcare Ltd., Coherus BioSciences Inc., CinnaGen Co., Alvotech Holdings S.A, Reliance Life Sciences Private Limited, Momenta Pharmaceuticals Inc., Bio-Thera Solutions Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., BioXpress Therapeutics SA, Alteogen Inc., Prestige BioPharma Pte. Ltd. _x000D_

_x000D_

#Access The Complete Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/report/humira-drug-global-market-report_x000D_

_x000D_

#Which Regional Markets Are Emerging As Key Hubs For The Humira Drug Market?#_x000D_

North America was the largest region in the humira drug market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the humira drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Customize Your Report Here:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=11934&type=smp_x000D_

_x000D_

#About The Business Research Company:#_x000D_

_x000D_

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_